allopurinol / Generic mfg. - LARVOL DELTA

Real-world outcome of low-frequency outpatient monitoring for venetoclax initiation in CLL: Single-center experience (ASH 2025) - "Prophylactic allopurinol was initiated one day prior to W1 of Ven induction. As of July 2025, twenty-five patients were transitioned to Ven in the outpatient setting. The median age was 70 (range: 53 – 86) years. 7 patients (28%) were IgVH mutated, 15 (60%) were unmutated, 1 was indeterminate (4%), and 2 were unknown (8%)."

Clinical • IO biomarker • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • IGH

Disseminated intravascular coagulation: An uncommon initial manifestation of AML presenting with embolic stroke (ASH 2025) - "Hematology was consulted, and empiric hydroxyurea and allopurinol were ordered for suspected AML. This case underscores the importance of recognizing prothrombotic DIC as a potentially life-threatening early manifestation of non-APL AML, particularly when accompanied by hyperleukocytosis and cytopenias. It reinforces the need for heightened clinical suspicion, early interdisciplinary coordination, and raises important questions regarding stroke risk stratification and anticoagulation strategies in patients presenting with leukemia-associated coagulopathy."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Atrial Fibrillation • Back Pain • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Ischemic stroke • Leukemia • Musculoskeletal Pain • Pulmonary Disease • Thrombocytopenia

Effect and mechanism of allopurinol in ALL maintenance therapy: Reducing hepatotoxicity and improving myelosuppression effect via TPMT inhibition and increased DNA-thioguanine levels (ASH 2025) - "Introduction: 6-Mercaptopurine (6-MP) based-maintenance therapy is essential to cure acute lymphoblastic leukemia (ALL). In conclusion, intensifying 6-MP dosing does not achieve adequate myelosuppression effect, but primarily increases the risk of hepatotoxicity by experiencing skewed metabolism. Low-dose 6-MP combined with allopurinol, rather than intensifying 6-MP dose, could be an alternative strategy for better efficacy and lower risk of hepatotoxicity."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Hepatology • Leukemia • NUDT15

Long-read whole genome sequencing improves clinical management in acute leukemia (ASH 2025) - "patient diagnosed withAML, both epigenomic and genomic data confirmed NPM1 mutation, pharmacogenomic profilingidentified a poor function phenotype of the ABCG2 (BCRP) transporter, which had not been tested priorto the prescription of allopurinol at a dose of 300 mg daily, administered for 7 days on two separateoccasions...Our findings underscore the value of~20x long-read whole genomic and epigenomic profiling for refined diagnosis, risk stratification, andsupportive care management in hematology/oncology. Overall, we show the strength of a rapid long-readsequencing to provide in a single run methylation data that can assist in preliminary diagnostic andprognostic calls and DNA sequencing data for actionable genetic and pharmacogenomic calls to promotepersonalized treatment strategy."

Clinical • Whole genome sequencing • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • ABCG2 • ARG1 • IDH1 • NPM1

Evaluation of ventoclax initiation prophylaxis and monitoring outcomes at each dose level and time point in patients with chronic lymphocytic leukemia: A real-world experience (ASH 2025) - "Background : Venetoclax (VEN)+obinutuzumab (VO) is an effective therapy for CLL/SLL requiring regularmonitoring for tumor lysis syndrome (TLS) during VEN ramp-up...Adult pts with CLL/SLL were eligible if they: (1) startedVO per-label outside of a clinical trial in 1L, or immediately after exposure in 1L to agents with differentmechanisms of action (i.e., BTKi, anti-CD20 only) of <30 days; (2) prior to VEN start, had either (i) lowphysician-determined tumor burden (TB) (i.e., all lymph nodes [LN] <5 cm and ALC <25 x 109/L), or (ii)medium physician-determined TB (i.e., any LN ≥5-<10 cm or ALC ≥25 x 109/L) with creatinine clearance≥80 mL/min; (3) had no strong CYP3A inhibitors or prophylactic rasburicase from 3 days prior to VENstart until end of VEN ramp-up; and (4) had VEN ramp-up in an outpatient setting.TB-related labs/imaging was assessed from 2 months prior to obinutuzumab initiation (i.e., index date)until VEN start...Prior to VEN ramp-up, all pts..."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Diabetes • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • IGH • TP53

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Mechanism of xanthine oxidase in flap ischemia-reperfusion injury and advances in targeted therapy: a mini review. (PubMed, Front Physiol) - "Allopurinol and febuxostat, xanthine oxidase inhibitor, primarily exerts its protective effects by inhibiting the activity of xanthine oxidase and reducing reactive oxygen species generation, thereby suppressing oxidative stress damage. Additionally, it may improve flap survival through other mechanisms, such as modulating inflammatory responses and suppressing apoptosis. This article systematically reviews the pathological mechanisms and therapeutic advances of skin flap ischemia-reperfusion injury, with a focus on exploring the role of xanthine oxidase inhibitors in flap protection by targeting and regulating oxidative stress pathways, aiming to provide new therapeutic strategies and theoretical basis for clinical prevention and treatment of skin flap ischemia-reperfusion injury."

Journal • Review • Cardiovascular • Inflammation • Reperfusion Injury

Risk of ischemic stroke in benzbromarone versus allopurinol users: a real-world cohort study using TriNetX. (PubMed, Clin Rheumatol) - "Benzbromarone use was associated with a higher long-term risk of ischemic stroke compared to allopurinol among individuals aged 20-84 years with hyperuricemia or gout. Key Points What is known: • Benzbromarone and allopurinol are two commonly prescribed urate-lowering therapies for hyperuricemia and gout. • The association between these medications and the risk of ischemic stroke remains uncertain. What is new here: • In this study, benzbromarone use was associated with a significantly higher risk of ischemic stroke compared to allopurinol use. • The adjusted hazard ratio for ischemic stroke was 1.296 (95% CI: 1.129-1.488, P = 0.0002) for benzbromarone versus allopurinol. Translational impact: • These findings suggest that benzbromarone may carry a higher long-term ischemic stroke risk than allopurinol, which could inform clinical decision-making in urate-lowering therapy selection."

Journal • Real-world evidence • Cardiovascular • Gout • Inflammatory Arthritis • Ischemic stroke • Rheumatology

Risk Factors for Drug-Induced Severe Cutaneous Adverse Reactions: A Real-World Pharmacovigilance Analysis. (PubMed, J Dermatol) - "Logistic regression identified older age, male sex, and 114 drugs as independent risk factors for drug-induced SCARs, including amlodipine (adjusted ROR = 2.89), bisoprolol (adjusted ROR = 3.52), and losartan (adjusted ROR = 2.77). In the non-Asian population, the strongest signals were observed for allopurinol (adjusted ROR = 98.52), cefotaxime (adjusted ROR = 68.52), and lamotrigine (adjusted ROR = 38.59), whereas apalutamide (adjusted ROR = 14.57), ipilimumab (adjusted ROR = 3.24), and acetylsalicylic acid (adjusted ROR = 2.85) were detected only in Asians...The Asian population had a significantly shorter TTO compared to the non-Asian population (p < 0.001). This study uses FAERS data to analyze risk factors for drug-induced SCARs, emphasizing early identification and discontinuation of suspected drugs to enhance patient safety."

Adverse events • Journal • Real-world evidence • Immunology

Novel iron-nickel bimetallic nanozyme with peroxidase-like activity for ultrasensitive uric acid detection and hyperuricaemia therapy evaluation. (PubMed, Nanoscale) - "Furthermore, we assessed serum UA levels in hyperuricemic rats treated with allopurinol and benzbromarone, demonstrating rapid drug efficacy evaluation. Our findings highlight the potential of Fe4Ni-NFs in UA detection and hyperuricemia management, suggesting broad applications in drug development and precision medicine. This work provided mechanistic insights into bimetallic nanozymes' POD-like activity and underscores their potential for biomedical applications, offering a new strategy for hyperuricemia diagnosis and treatment."

Journal • Metabolic Disorders

Benzbromarone Inhibits Renal URAT1 and Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats, Independent of Its Uricosuric Effects. (PubMed, J Diabetes Res) - "Recent studies have confirmed that allopurinol, an inhibitor of xanthine oxidase (XO), does not have any beneficial effects on DKD...BZ treatment significantly inhibited GLUT9 expression but had no effect on XO and uricase expression in diabetic rats. BZ treatment significantly protects against renal damage in STZ-induced diabetic rats independent of its uricosuric effects, possibly because of its inhibition of renal URAT1."

Journal • Preclinical • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease

Allopurinol increases DNA-thioguanine nucleotides during maintenance therapy in pediatric acute lymphoblastic leukemia. (PubMed, Haematologica) - "Not available."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Urolithiasis Due to Adenine Phosphoribosyl Transferase (APRT) Deficiency: A Case Report and Practical Recommendations in Children. (PubMed, Arch Esp Urol) - "Early intervention with therapeutic and dietetic measures could preserve the normal renal function of the young patient."

Journal • Infectious Disease • Metabolic Disorders • Nephrology • Renal Calculi • Renal Disease • Respiratory Diseases • Urolithiasis

Febuxostat alleviates gout-associated hyperuricemia and inflammation by downregulating IL1A to modulate TLR2/TLR4/NF-κB signaling pathway. (PubMed, Int Immunopharmacol) - "Feb treats gout by downregulating IL1A to modulate the TLR2/TLR4/NF-κB signaling pathway, making IL1A a potential biomarker for gout management and highlighting the therapeutic prospects of Feb in targeting inflammation-related pathways."

Journal • Gout • Inflammation • Inflammatory Arthritis • Rheumatology • IL18 • IL1A • IL1B • IL6 • TLR2 • TLR4 • TNFA

Cardiovascular morbidity and mortality in gout: is gout an Independent risk Factor? (PubMed, Expert Opin Pharmacother) - "Colchicine use is associated with reduced acute CV events both in general population with CAD and in gout. Treat-to-target (T2T) serum urate approach entails titrating ULT by monitoring serum urate levels and gout flares. Allopurinol, the most commonly used and inexpensive ULT, in approved daily doses of 300-800 mg can achieve target serum urate less than 6 mg/dl or 5 mg/dl."

Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Gout • Immunology • Inflammation • Inflammatory Arthritis • Metabolic Disorders • Myocardial Infarction • Rheumatology

Insights on genomic profiles of drug resistance and virulence in a cohort of Leishmania infantum isolates from the Mediterranean area. (PubMed, Parasit Vectors) - "The prevalence of drug-resistance biomarkers in Leishmania infantum strains from the Mediterranean region, as revealed by this study, underscores the critical need for routine resistance surveillance in managing clinical leishmaniosis. These findings not only inform current clinical practice but also pave the way for more effective management strategies in the future."

Journal • AQP1

Allopurinol-Induced Lymphadenopathy: A Case Report. (PubMed, ACR Open Rheumatol) - No abstract available

Journal

Febuxostat Versus Allopurinol Use in Gout Patients: A Real-World Study. (PubMed, Cureus) - "While the febuxostat group showed more events, this was associated with a higher prevalence of almost all risk factors. Interpreting study results and applying them practically remain difficult given the constellation's commonality in clinical life; therefore, careful consideration is necessary."

Journal • Real-world evidence • Cardiovascular • Gout • Inflammatory Arthritis • Rheumatology

FARFOOD: a database of potential interactions between food compounds and drugs. (PubMed, BioData Min) - No abstract available

Journal

Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study. (PubMed, Nephrology (Carlton)) - "In conclusion, no statistically significant difference in the risk of cardiovascular events was observed in people with chronic kidney disease who were newly prescribed febuxostat compared with those newly treated with allopurinol."

Clinical • Journal • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Myocardial Infarction • Nephrology • Renal Disease

Acute Interstitial Nephritis and Liver Injury After Long-Term Semaglutide Use (KIDNEY WEEK 2025) - "Long term medications included semaglutide, lisinopril, and allopurinol. Aspirin and atorvastatin were recently initiated for a transient ischemic attack...Prednisone dose was increased, and she was slowly tapered off steroids with Cr remaining stable at 1.6 mg/dL...Figure - The interstitium shows severe inflammatory infiltrates including lymphocytes, plasma cells, and numerous eosinophils in clusters (up to > 100 eosinophils per HPF). Tubules show focally severe tubulitis."

Acute Kidney Injury • Anorexia • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Eosinophilia • Genetic Disorders • Glomerulonephritis • Hepatology • Hypertension • Liver Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Unveiling prognostic indicators in canine leishmaniosis: two decades of evidence. (PubMed, Parasit Vectors) - "Our study highlights important risk factors for poor prognosis in CanL that should be carefully considered by clinicians and researchers when managing sick dogs, particularly regarding therapy decision-making."

Biomarker • Journal • Retrospective data

Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma (ASH 2024) - P2 | "However, PFS was inferior for patients (pts) treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone every 21 days) compared with other regimens, supporting intensification of therapy beyond R-CHOP-21 in this entity. (eg. Allopurinol, co-trimoxazole). Study enrolment, safety and efficacy analyses are ongoing."

Clinical • P2 data • Alopecia • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • PD-L2

Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study. (PubMed, Support Care Cancer) - "Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Oncology

Allopurinol Add-on 6-Mercaptopurine Strategy Improves Efficacy and Reduces Toxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. (PubMed, Clin Pharmacol Ther) - "Metabolite levels (6-thioguanine nucleotides (6-TGNs), methyl mercaptopurine nucleotides (6-MMPN), DNA-thioguanine (DNA-TG)), thiopurine methyltransferase (TPMT) activity were measured pre- and post-combination. LOESS regression estimates indicated significant fluctuations in WBC, ANC, and 6-MP/allopurinol dosage ratios following 3 months of combination therapy (P  1 m2, when co-administered with allopurinol (50 mg/m2/day)."

Journal • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Pediatrics